Beyond Air Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals

Garden city, n.y., march 20, 2024 (globe newswire) -- beyond air, inc. (nasdaq: xair) (“beyond air” or the “company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (no) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate beyond cancer, ltd. (“beyond cancer”)), today announced that it has entered into a securities purchase agreement with healthcare focused institutional investors and accredited investors, including certain directors and officers of the company, whereby the investors have agreed to purchase 9,638,556 shares of the company's common stock and warrants to purchase up to an aggregate of 9,638,556 shares of common stock at a purchase price of $1...

Commercial demand for lungfit® ph increasing; manufacturing of upgraded devices is ramping up to meet growing demand

Garden city, n.y., jan. 18, 2024 (globe newswire) -- beyond air, inc. (nasdaq: xair) (“beyond air” or the “company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (no) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate beyond cancer, ltd.

No dose limiting toxicities were reported in the first cohort of ultra-high concentration of nitric oxide administered at 25,000 parts per million (ppm)

Garden city, n.y., nov. 15, 2023 (globe newswire) -- beyond air, inc. (nasdaq: xair) (“beyond air” or the “company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (no) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate beyond cancer, ltd. (“beyond cancer”)), today announced that steve lisi, chairman and chief executive officer of beyond air, will participate in a fireside discussion and one-on-one meetings at the piper sandler healthcare conference being held november 28-30, 2023 in new york city.

Beyond Air (XAIR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Beyond Air, Inc. (XAIR) Q3 2024 Earnings Call Transcript

Beyond Air, Inc. (XAIR) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $0.43 per share a year ago.

Beyond Air, Inc. (NASDAQ:XAIR ) Q2 2024 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Edward Barger - Head of Investor Relations Steve Lisi - Chairman and Chief Executive Officer Duncan Fatkin - Chief Commercial Officer Douglas Larson - Chief Financial Officer Conference Call Participants Jeremy Jacoby - Truist Securities Marie Thibault - BTIG Matt Kaplan - Ladenburg Thalmann Operator Good afternoon and welcome everyone to the Beyond Air Financial Results Call for the Fiscal Quarter ended September 30, 2023. At this time, participants are in a listen-only mode.

GARDEN CITY, N.Y., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd.

GARDEN CITY, N.Y. and HAMILTON, Bermuda, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced that Beyond Cancer, Ltd. will present two proffered posters at the upcoming American Association for Cancer Research-National Cancer Institute-European Organisation for Research and Treatment of Cancer (AACR-NCI-EORTC) International Conference on Molecular Targets and Cancer Therapeutics 2023, which is scheduled to be held October 11th – 15th in Boston, Massachusetts. Abstracts are scheduled to be released to AACR-NCI-EORTC registrants today 12:00 pm U...

The realm of penny stocks, often characterized by their affordable price tag, has become a hotspot for investors eager to seize the stock market's opportunities. These stocks, typically valued under $5, carry inherent risks and promise impressive rewards.

Beyond Air, Inc. (NASDAQ:XAIR ) Q1 2024 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Edward Barger - Head of Investor Relations Steve Lisi - Chairman and Chief Executive Officer Duncan Fatkin - Chief Commercial Officer Douglas Larson - Chief Financial Officer Conference Call Participants Les Sulewski - Truist Securities Marie Thibault - BTIG Scott Henry - ROTH Capital Jason Bednar - Piper Sandler Matt Kaplan - Ladenburg Thalmann Yale Jen - Laidlaw & Company Operator Good afternoon and welcome everyone to the Beyond Air Financial Results Call for the Fiscal Quarter ended June 30, 2023. At this time, all participants are in a listen-only mode.

Beyond Air, Inc. (XAIR) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to loss of $0.37 per share a year ago.

GARDEN CITY, N.Y., July 24, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd.